Latest Anthracyclines Stories
PRINCETON, N.J., Nov.
COLUMBIA, Md., Nov.
PRINCETON, N.J., Oct.
COLUMBIA, Md., Oct. 1 /PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN) announced today that interim data from its Phase I/II DIGNITY trial of ThermoDoxÂ® in Recurrent Chest Wall (RCW) Breast Cancer were presented at the poster session at the 2010 Breast Cancer Symposium.
COLUMBIA, Md., Sept. 21 /PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN) announced today that an abstract on its Phase I/II DIGNITY trial of ThermoDoxÂ® in Recurrent Chest Wall (RCW) Breast Cancer has been accepted for a poster session at the 2010 Breast Cancer Symposium.
COLUMBIA, Md., Sept.
PRINCETON, N.J., Sept. 1 /PRNewswire/ -- Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.
COLUMBIA, Md., Aug.
PRINCETON, N.J., June 21 /PRNewswire/ -- Celator Pharmaceuticals today announced that it has expanded its research agreement with Cephalon, Inc. (Nasdaq: CEPH).
PRINCETON, N.J., June 14 /PRNewswire/ -- Celator Pharmaceuticals today announced that new data from a preclinical leukemia study in mice demonstrate that its lead product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, alone or in combination with clofarabine or azacytidine can improve treatment outcomes compared to the combination of either agent with the conventional (unencapsulated) cytarabine:daunorubicin regimen.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.